Physician profile
Jon Payne
NPI 1699120949
$6,484.78
in general payments reported to CMS, 2019-2025
44 companies · $1,918 in 2025
The $1,918 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.62 · 2020: $37.21 · 2021: $236 · 2022: $1,474 · 2023: $1,352 · 2024: $1,406 · 2025: $1,918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,676.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $714.15 | 2022-2025 | |
| Glaxosmithkline, LLC. | $621.40 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $606.37 | 2022-2025 | |
| Pfizer INC. | $551.67 | 2023-2025 | |
| Novo Nordisk INC | $498.25 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $448.53 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $415.82 | 2022-2025 | Jardiance |
| Lilly USA, LLC | $283.69 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $245.53 | 2020-2025 | Repatha, Otezla |
| Exact Sciences Corporation | $207.12 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $196.56 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Idorsia Pharmaceuticals US INC | $154.36 | 2022-2025 | Quviviq, Quviviq |
| Sanofi-Aventis U.S. LLC | $140.90 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.14 | 2022-2025 | Xifaxan |
| Corcept Therapeutics | $133.05 | 2024-2025 | Korlym |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $91.67 | 2022-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $89.48 | 2023-2025 | Spravato |
| Antares Pharma, INC. | $84.76 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Astellas Pharma US INC | $82.04 | 2022-2025 | Veozah |
| Paratek Pharmaceuticals, INC. | $72.53 | 2022-2025 | Nuzyra, Xhance |
| Corium, LLC | $69.88 | 2023-2025 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $48.02 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $46.44 | 2024-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $43.57 | 2021 | |
| Ironwood Pharmaceuticals, INC | $41.25 | 2021-2022 | |
| Halozyme INC | $41.17 | 2023 | |
| Lundbeck LLC | $37.74 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $35.18 | 2024-2025 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.55 | 2024-2025 | Caplyta |
| Amarin Pharma, INC. | $31.70 | 2022 | |
| Abbott Laboratories | $31.55 | 2022-2023 | Freestyle Libre 3 |
| Boston Scientific Corporation | $29.18 | 2025 | Wavewriter Alpha Prime 16 |
| Currax Pharmaceuticals LLC | $28.99 | 2021-2022 | |
| Medtronic, INC. | $27.17 | 2025 | Inceptiv |
| Axsome Therapeutics, INC. | $24.70 | 2025 | Symbravo |
| E.R. Squibb & Sons, L.L.C. | $23.50 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $20.62 | 2019 | |
| Scilex Pharmaceuticals INC. | $18.06 | 2024 | |
| Dynavax Technologies Corporation | $17.54 | 2024 | Heplisav-B |
| Kowa Pharmaceuticals America, INC. | $16.83 | 2025 | Zoryve |
| Renalytix Ai, INC. | $15.46 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Allergan, INC. | $12.78 | 2020 | |
| Sunovion Pharmaceuticals INC. | $12.11 | 2022 | |
| Fidia Pharma USA INC. | $5.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.